← All medicines

Cancer medicines

Inavolisib

Independent educational summary · Sources checked November 20, 2026

A PI3K-pathway inhibitor used with other medicines for eligible previously treated breast cancer.

Profile scope: Inavolisib. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Fatigue, nausea, rash, reduced appetite, or headache may occur.

Serious risks and warning signs

Severe high-glucose complications, mouth injury, diarrhea, and colitis symptoms require assessment. Extreme thirst, frequent urination, fruity breath, confusion, breathing changes, inability to drink, or bloody stools needs prompt help.

A question for your healthcare team

What glucose, mouth-care, and diarrhea-prevention plans apply before and during the combination regimen?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.